Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis.

  • Fabris M
  • Tolusso B
  • Di Poi E
 et al. 
  • 7


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


OBJECTIVE: To define the frequency of the exon 6 tumor necrosis factor-alpha (TNF-alpha) receptor II (TNFRII) gene polymorphism in severe and mild-moderate rheumatoid arthritis (RA) and its possible influence on anti-TNF-alpha treatment responsiveness. METHODS: Two cohorts of patients with RA, the first (n = 97) defined as methotrexate responders (MTX-R) with mild-moderate synovitis, and the second (n = 78) defined as nonresponders to combination therapy and receiving anti-TNF-alpha treatment because of their severe and aggressive disease (TNF-T), were studied retrospectively and compared to age, sex, and ethnically matched controls (n = 84). In the prospective study, 66 patients with severe RA were followed over the first 6 months of anti-TNF-alpha therapy and their response was examined according to genotype. RESULTS: We observed a trend towards an increased frequency of the GG genotype in patients with severe RA (6.4%) in comparison with patients with mild-moderate disease (3.1%) and controls (1.2%). When looking at the response to anti-TNF-alpha therapy, we observed that after 12 weeks of treatment, 37.8% of the TT versus 10.7% of the TG/GG patients passed from high to medium-low disease activity (p = 0.03). CONCLUSION: In our cohorts of patients selected by response to the conventional therapy and by disease severity, our preliminary study results showed a trend towards a higher prevalence of the GG genotype for the exon 6 TNFRII polymorphism in the less responsive patients with more aggressive disease. We also found a lower degree of response to anti-TNF-alpha treatments in patients carrying the G allele.

Author-supplied keywords

  • Adult
  • Age Distribution
  • Aged
  • Aged, 80 and over
  • Antigens, CD
  • Arthritis, Rheumatoid
  • Case-Control Studies
  • Drug Therapy, Combination
  • Female
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Incidence
  • Italy
  • Male
  • Methotrexate
  • Middle Aged
  • Odds Ratio
  • Pharmacogenetics
  • Polymorphism, Genetic
  • Prednisone
  • Probability
  • Prognosis
  • Receptors, Tumor Necrosis Factor
  • Receptors, Tumor Necrosis Factor, Type II
  • Reference Values
  • Retrospective Studies
  • Risk Factors
  • Severity of Illness Index
  • Sex
  • Sex Distribution
  • Treatment Outcome
  • drug therapy
  • epidemiology
  • genetics
  • therapeutic use

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Martina Fabris

  • Barbara Tolusso

  • Emma Di Poi

  • Roberta Assaloni

  • Luigi Sinigaglia

  • Gianfranco Ferraccioli

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free